Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.10 per unit.
With FTXH trading at a recent price near $26.42 per unit, that means that analysts see 13.91% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Seagen Inc (Symbol: SGEN), Prestige Consumer Healthcare Inc (Symbol: PBH), and Ironwood Pharmaceuticals Inc (Symbol: IRWD). Although SGEN has traded at a recent price of $133.47/share, the average analyst target is 22.46% higher at $163.45/share. Similarly, PBH has 15.62% upside from the recent share price of $55.64 if the average analyst target price of $64.33/share is reached, and analysts on average are expecting IRWD to reach a target price of $12.67/share, which is 14.42% above the recent price of $11.07. Below is a twelve month price history chart comparing the stock performance of SGEN, PBH, and IRWD:
Combined, SGEN, PBH, and IRWD represent 9.22% of the First Trust Nasdaq Pharmaceuticals ETF. Below is a summary table of the current analyst target prices discussed above:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| First Trust Nasdaq Pharmaceuticals ETF | FTXH | $26.42 | $30.10 | 13.91% |
| Seagen Inc | SGEN | $133.47 | $163.45 | 22.46% |
| Prestige Consumer Healthcare Inc | PBH | $55.64 | $64.33 | 15.62% |
| Ironwood Pharmaceuticals Inc | IRWD | $11.07 | $12.67 | 14.42% |
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
